Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982601 | 0.85 | PSMB8 (0.30) | PSMB8 | |
| SCHEMBL10108551 | 0.83 | — | — | |
| SCHEMBL11982600 | 0.77 | PSMB8 (0.33) | PSMB8 | |
| SCHEMBL11903308 | 0.72 | KMT2A (0.34) | — | |
| SCHEMBL10108330 | 0.62 | CYP1A2 (0.31) | — | |
| SCHEMBL10108550 | 0.61 | — | — | |
| SCHEMBL10108566 | 0.58 | — | — | |
| SCHEMBL10108564 | 0.58 | — | — | |
| SCHEMBL10108324 | 0.58 | ALDH1A1 (0.36) | — | |
| SCHEMBL14355119 | 0.53 | PSMB8 (0.42) | PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PSMB8 4478/4885 |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, MAP3K19 | PSMB8 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.